A high-conviction short opportunity exists in aTyr Pharma (ATYR), as its lead drug is believed to be based on flawed science with a near-zero chance of success. The overhyped quantum computing sector also presents shorting opportunities, with Quantum Computing Inc. (QUBT) viewed as a potential "scam" and IonQ (IONQ) expected to fall below $40 per share. Another potential short target is Soundhound AI (SOUN) due to significant bearish sentiment. For a contrarian long position, consider buying high-quality insurer UnitedHealth Group (UNH) during its period of market fear for a potential recovery. Investors looking for AI exposure beyond NVIDIA could research its supplier Coherent (COHR), which is being considered as a potential buy.

aTyr Pharma (ATYR)

• The speaker presents a detailed and extremely bearish thesis on ATYR, stating with certainty that its lead drug, esfitomib, for sarcoidosis "does not work" and has a probability of success that is "practically a zero."
• The Scientific Thesis (Simplified):
  • The company's hypothesis is based on a protein called AARS. In very rare cases, patients develop antibodies to AARS, which leads to a specific lung disease (myositis/ILD).
  • ATYR's drug is a synthetic version of AARS. The theory is that by giving more AARS to patients with sarcoidosis (who do not have these antibodies), it will have a beneficial, anti-inflammatory effect.
  • The speaker argues this logic is flawed because the sarcoidosis patients' AARS pathway isn't broken to begin with. Supplementing it is unlikely to fix a problem caused by something else entirely.
• Key Bearish Points:
  • Failed Precedent: The company already tried this exact same therapeutic idea with a previous drug (ATYR 1940) in a similar disease (myositis), and it failed. The speaker questions why it would work now in a different disease.
  • Weak Data: The speaker repeatedly calls the preclinical and clinical data "weak" and "bad."
  • Inexperienced Team: The speaker notes the drug was primarily developed by a postdoc with no prior pharma industry experience, and the company lacks a strong track record of success.
  • Market Implied Odds: The options market is pricing in a roughly 75% chance of failure. The speaker believes even this is "vastly overestimating the likelihood of success" and calls the 25% chance of success implied by the market "a gift" for those looking to bet against the stock.

Takeaways

• The speaker has a high-conviction short thesis on ATYR. The analysis suggests the fundamental science behind the company's lead drug is deeply flawed.
• Investors should be aware of the significant risks highlighted, including the failure of a similar predecessor drug and what the speaker describes as weak supporting data.
• The speaker views the stock as a potential "zero" and compares the situation to other failed biotech stories like INMB.

Quantum Computing Sector

• The speaker expresses a generally bearish sentiment towards the quantum computing sector, comparing the current excitement to the "weed bubble."

• D-Wave Quantum (QBTS):

  • While the stock price has been a "monster" reaching $18, the speaker is highly skeptical of its business fundamentals.
  • Mocks the company's low revenue, joking that a local laundromat has higher sales and better growth.

• IonQ (IONQ):

  • The speaker has a specific bearish price expectation, stating, "I bet you IonQ goes below 40."

• Quantum Computing Inc. (QUBT):

  • This is the most bearish call in the sector. The speaker labels the company a "scam" and "much faker than the others."
  • The company's revenue is noted as being extremely low ($61K in the quarter, down 75% year-over-year) for its $2.1 billion market cap.
  • The speaker is actively considering shorting more of the stock.

Takeaways

• The speaker believes the quantum computing sector is in a speculative bubble and is positioned for a downturn.
• QUBT is identified as a potential high-conviction short due to being a perceived "scam" with poor financial results relative to its valuation.
• A specific price target was mentioned for IONQ, suggesting a belief that the stock has significant downside from its current levels.

CoreWeave (Private)

• The speaker notes a sharp, recent drop in the private market valuation of CoreWeave, from $150 to $100 per share, calling it a "sloppy situation."
• Potential Negative Catalysts Mentioned:
  • Lockup Expirations: The end of a lockup period could be allowing early investors and insiders to sell their shares, creating downward pressure.
  • Poor Cash Collection: The speaker highlights a major red flag from the company's financials: "they basically didn't collect any invoices in Q1." This raises concerns about cash flow and the quality of their reported revenue.

Takeaways

• Although a private company, the discussion on CoreWeave provides insight into potential stress in the AI infrastructure space.
• The combination of expiring lockups and poor cash collection are significant risk factors that investors in similar public companies (like GPU makers and data centers) should be mindful of.

UnitedHealth Group (UNH)

• The speaker is considering a bullish comeback trade on UNH.
• The idea is to buy into a high-quality company when market sentiment is overly negative and people are "screaming bloody murder."
• The speaker believes this type of panic creates a potential buying opportunity for long-term investors.
• It's also mentioned that this is a stock that a value investor like Warren Buffett might consider buying.

Takeaways

• UNH is presented as a potential contrarian long idea.
• The investment thesis is based on buying a fundamentally strong company during a period of market fear, with the expectation of an eventual recovery.

NVIDIA (NVDA) and Suppliers

• The speaker mentions adding NVIDIA suppliers to their watchlist, specifically Light (LITE) and Coherent (COHR).
• The sentiment is cautiously bullish or at least neutral, stating "not shorting light" and "almost want to buy coherent."
• This suggests a belief that even if NVIDIA's stock is high, there may be value in the companies that supply the components for its AI chips.

Takeaways

• Investors interested in the AI hardware theme but wary of NVIDIA's high valuation could research its key suppliers.
• Coherent (COHR) was specifically mentioned as a potential buy.

Newegg Commerce (NEGG)

• The speaker notes the stock has been on a "crazy run" up to $114.
• The situation is compared to GameStop, with a major activist shareholder involved.
• The speaker expresses skepticism about the sustainability of the run, questioning if the activist has enough capital to keep buying the stock at its new, higher valuation.
• The borrow rate to short the stock is mentioned as being extremely high (600%), making it very expensive and risky to bet against.

Takeaways

• NEGG is identified as a highly volatile "meme stock."
• While the run-up has been significant, the speaker implies it may be disconnected from fundamentals and driven by a speculative squeeze.
• Shorting the stock is extremely risky due to the high borrow cost.

General Stock Market Commentary

• PGen (Precigen, PGEN): The speaker considers taking a "very small, long position" not on a strong conviction, but as a way to force himself to watch and research the stock more closely.
• Crystal Pie (2228.HK): A new Hong Kong biotech IPO that the speaker analyzed and deemed unattractive and a potential short. The reasoning was a high $2 billion market cap relative to its $400 million in cash.
• Sarepta (SRPT): Mentioned as a stock that was a great buy when it was in the "low teens" and people were panicking. Now that it has recovered, the speaker has moved it from a "large cap" to a "mid cap" on their watchlist, implying its best days may be behind it for now.
• Soundhound AI (SOUN): The speaker explicitly states, "We want a short-sum Soundhound as well."
• Ethereum (ETH): The speaker is dismissive of Ethereum, questioning the purpose of an "ETH treasury" and stating flatly, "ETH solves nothing."
• Large Cap Biopharma: The speaker lists a global watchlist of large-cap pharma companies, including Roche (ROG.SW), Novartis (NVS), AstraZeneca (AZN), and Novo Nordisk (NVO), as a way to track the entire sector. This implies a strategy of monitoring global leaders in the space.